Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-β-1a for Ebola virus disease
ISRCTN17414946Phase 2Completed
- Sponsor
- Sustainable health Foundation (FOSAD) & Center of Excellence for Training on Research and Priority Diseases (CEFORPAG)
- Start
- Mar 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon beta-1a in Ebola virus disease (EVD), sponsored by Sustainable health Foundation (FOSAD) & Center of Excellence for Training on Research and Priority Diseases (CEFORPAG). Primary endpoint: Viral load reduction/clearance from blood. Started Mar 2015; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on ISRCTN17414946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17414946.